financetom
Business
financetom
/
Business
/
Capital Power Reaffirms 2025 Guidance Despite Lower Q3 Earnings
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Capital Power Reaffirms 2025 Guidance Despite Lower Q3 Earnings
Oct 29, 2025 6:12 AM

08:46 AM EDT, 10/29/2025 (MT Newswires) -- Capital Power ( CPXWF ) reported lower net income in the third quarter, missing analysts' expectations, although the company still reaffirmed its 2025 guidance.

Capital Power ( CPXWF ) booked a net income of C$154 million, or $0.94 per share, falling from $179 million, or $1.32 per share, posted in the year-ago period.

The company's earnings per share also fell below the $1.02 EPS consensus forecast compiled by FactSet.

Revenue increased to $1.21 billion from $1.03 billion while electricity generation rose to 13,374 gigawatt hours from 11,001 GWh.

"Our third quarter results reflect the continued execution of our strategy to strengthen our U.S. platform and expand our contracted cash flows," president and chief executive officer Avik Dey said.

Capital Power ( CPXWF ) reaffirmed its revised guidance for 2025 despite updates to planned outages and delays on its Alberta projects. The company outlined an adjusted EBITDA target of $1.50 billion to $1.65 billion, adjusted funds from operations of $950 million to $1.1 billion, and sustaining capital expenditures of $215 million to $245 million.

Meanwhile, Sandra Haskins is retiring as Capital Power's ( CPXWF ) chief financial officer and senior vice president for finance on Dec. 31 after a 23-year tenure. Haskins will remain in an advisory capacity until the end of the first quarter of 2026.

Scott Manson, currently chief accounting officer and treasurer, will transition to interim SVP finance and CFO as the company searches for a permanent replacement.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Redwire Plans to Appoint Chris Edmunds as Chief Financial Officer
Redwire Plans to Appoint Chris Edmunds as Chief Financial Officer
Oct 7, 2025
08:17 AM EDT, 10/07/2025 (MT Newswires) -- Redwire ( RDW ) said Tuesday it intends to appoint Chris Edmunds as chief financial officer, replacing Jonathan Baliff, who will retire, effective Nov. 30. Edmunds currently serves as the company's chief accounting officer. Baliff will serve as a consultant through December 2026, Redwire ( RDW ) said. The company's shares were up...
IonQ Closes Vector Atomic Acquisition
IonQ Closes Vector Atomic Acquisition
Oct 7, 2025
08:13 AM EDT, 10/07/2025 (MT Newswires) -- IonQ ( IONQ ) said Tuesday it closed its acquisition of California-based quantum sensing company Vector Atomic. The company said the all-stock deal adds precision atomic clocks, inertial sensors, and synchronization hardware to its computing and networking stack. IonQ ( IONQ ) shares were up over 2% in recent premarket activity. ...
Telomir Says Investigational Therapy Reactivates Tumor Suppressor Genes in Preclinical Models
Telomir Says Investigational Therapy Reactivates Tumor Suppressor Genes in Preclinical Models
Oct 7, 2025
08:17 AM EDT, 10/07/2025 (MT Newswires) -- Telomir Pharmaceuticals ( TELO ) said Tuesday that preclinical results show that its investigational therapy Telomir-1 reactivated two tumor suppressor genes, potentially preventing the spread of cancer and improving responses to chemotherapy. The results showed that the experimental therapy reactivated the MASPIN and RASSF1A genes through DNA methylation reset in prostate cancer models,...
Fractyl Health Says Obesity Drug Candidate Shows Weight Loss in Preclinical Trial
Fractyl Health Says Obesity Drug Candidate Shows Weight Loss in Preclinical Trial
Oct 7, 2025
08:17 AM EDT, 10/07/2025 (MT Newswires) -- Fractyl Health ( GUTS ) said Tuesday that new preclinical data from its obesity candidate RJVA-002 showed 30% weight loss in mice after a single dose, with no adverse effects observed. The company said the study used a diet-induced obesity model with humanized GIP receptors and demonstrated a dose-dependent reduction in body weight...
Copyright 2023-2026 - www.financetom.com All Rights Reserved